Enveric Biosciences

02/27/2026

Enveric’s CEO, Joseph Tucker, explains the potential benefits of EB-003's dual mechanism that selectively engages both the 5-HT2A and 5-HT1B receptors to promote neuroplasticity without triggering unwanted effects. Learn more in Drug Discovery News: https://bit.ly/3MQCUgH

02/27/2026

Medium details new insight into how Enveric's next-generation neuroplastogens, EB-003, may separate the therapeutic benefits of psychedelics from hallucinogenic effects, potentially making treatment for neuropsychiatric disorders more accessible. https://bit.ly/3Mowqpk

02/26/2026

Microdose details the withdrawal of a Post Grant Review petition filed against Enveric’s ‘276 patent, reinforcing the strength of the Company’s intellectual property estate for its pipeline of next-generation, psychedelic-inspired therapeutics. For more info, visit: https://bit.ly/3MM7ZlO

02/26/2026

Pharma Device News highlights the differentiated profile of Enveric’s neuroplastogen, EB-003, with preclinical data demonstrating a dual-pathway mechanism that activates therapeutic signaling downstream of the 5-HT2A receptor without inducing hallucinations, reinforcing the Company’s potential to deliver a more scalable and accessible treatment for neuropsychiatric disorders. Learn more: https://bit.ly/3OMcI7z

02/25/2026

Our CEO, Joseph Tucker, Ph.D., comments on the withdrawal of Gilgamesh's petition against Enveric’s ‘276 patent. For more details, visit: https://bit.ly/4scaxZv

02/25/2026

Enveric has announced that the previously announced Post-Grant Review (PGR) petition filed by Gilgamesh Pharmaceuticals against Enveric’s issued U.S. Patent No. 12,138,276 (the ‘276 patent) has been withdrawn. This action follows Enveric’s filing of a Request for Discretionary Denial of the petition. As a result of this action, there are no remaining challenges currently pending against Enveric’s patent. https://bit.ly/4scaxZv

02/23/2026

A recent academic study published in Nature used BRET assays and complementary techniques to dissect 5-HT2A signaling mechanisms. The findings suggest that therapeutic effects and hallucinations may arise from separable intracellular mechanisms, underscoring the potential of non-hallucinogenic neuroplastogens to better address neuropsychiatric disorders. Read more in Meditech Today:

For much of the past decade, the psychedelic renaissance has revolved around experience. Carefully supervised psilocybin sessions. Structured integration.

02/20/2026

New mechanistic findings from Enveric’s BRET assay data evaluating its lead candidate, EB-003, were highlighted by Microdose, reinforcing its potential as a non-hallucinogenic neuroplastogen designed to support more scalable treatment paradigms. Read it here: https://bit.ly/4rqhRR8

02/20/2026

Findings from a recent independent Nature study indicate that therapeutic benefit and hallucinations may arise from distinct intracellular pathways, strengthening confidence in the scientific foundation of Enveric's non-hallucinogenic neuroplastogen, EB-003. For details: https://bit.ly/3ZHJNnB

02/19/2026

Drug Discovery News highlights Enveric's EB-003 as part of the next wave of psychedelics that are focused on separating therapeutic neuroplasticity from hallucinations to create drugs that are scalable, easier to administer, and reduce treatment burden. Read it here: https://bit.ly/3MQCUgH

02/19/2026

Our CEO, Joseph Tucker, comments on receptor engagement assay data for EB-003 demonstrating biologically relevant engagement of both Gq and β-arrestin pathways downstream of 5-HT A. Learn more: https://bit.ly/3ZHJNnB

02/19/2026

Enveric Biosciences announced new mechanistic data demonstrating that its lead candidate, EB-003, activates both Gq- and β-arrestin-mediated signaling downstream of the 5-HT A receptor, pathways linked in peer-reviewed studies to antidepressant and anxiolytic effects. For more info: https://bit.ly/3ZHJNnB